NCT00572078View on ClinicalTrials.gov

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

January 23, 2008

Primary Completion Date

January 4, 2011

Study Completion Date

September 14, 2014

Conditions

SOLID TUMORS

Interventions

DRUG

Sorafenib

Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID

Trial Locations (1)

46202

Indiana University Cancer Center, Indianapolis

Sponsors

Collaborators (2)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Bayer

INDUSTRY

lead

Safi Shahda

OTHER